Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASDAQ 4,034.16 11.47 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,091.52 -40.05 -1.28%
FTSE 100 6,541.61 -42.15 -0.64%
DAX 9,173.71 -165.46 -1.77%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,814.31 143.05 0.63%

Lilly to Host Conference Call to Discuss Trial Design of New Solanezumab Phase 3 Study

Lilly to Host Conference Call to Discuss Trial Design of New Solanezumab Phase
                                   3 Study

PR Newswire

INDIANAPOLIS, July 3, 2013

INDIANAPOLIS, July 3, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)
will host a conference call to discuss key elements of the trial design for
EXPEDITION3, its third Phase 3 trial for solanezumab. Lilly's solanezumab is a
monoclonal antibody being studied as a potential therapy for patients with
mild Alzheimer's disease.  The conference call will be held from 9:00 a.m. to
9:45 a.m. EDT on Friday, July 12, 2013.

A live audio webcast will be available on the Webcasts & Presentations section
of Lilly's Investor website at 
Subsequently, a replay of the presentation will be available on this same

Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers
—through medicines and information —for some of the world's most urgent
medical needs. Additional information about Lilly is available at P-LLY

This press release contains certain forward-looking statements about
solanezumab. This release reflects Lilly's current beliefs; however, as with
any pharmaceutical product, there are substantial risks and uncertainties in
the process of development and commercialization. There is no guarantee that
future study results and patient experience will be consistent with study
findings to date, or that solanezumab will be approved as a product or will
prove to be commercially successful. For further discussion of these and other
risks and uncertainties, see Lilly's filings with the United States Securities
and Exchange Commission. Lilly undertakes no duty to update forward-looking

Refer to: (317) 224-5331, - Stefanie Prodouz (Media)
          (317) 655-6874, - Philip Johnson


SOURCE Eli Lilly and Company

Sponsored Links
Sponsored Links